Efficacy of the Oral Plasma Kallikrein Inhibitor Sebetralstat (KVD900) by Attack Location in a Phase 2 Clinical Trial in Patients with Hereditary Angioedema
YOU ARE NOW LEAVING KALVISTA.COM
You are now being directed to another KalVista website that contains information about specific treatment(s)
